Recently, immunotherapies including CTLA-4 and PD-1 checkpoint inhibitors and targeted BRAF and MEK signal transduction inhibitors have been utilized for the treatment of advanced disease. [7] [8] [9] [10] While effective, these systemic therapies produce variable responses with a low rate of complete response, have significant documented toxicity profiles, and high health-related costs. The ideal timing for commencement and duration of treatment are also not defined. Multiple directed locoregional therapies have been investigated for the treatment of in-transit disease, and these have been repeatedly reported as safe, relatively efficacious and may improve progression-free survival. 11 Such locoregional treatments therefore remain relevant, providing an important intermediate therapeutic option for patients unsuitable for surgery.
Intralesional (IL) therapies involve a high dose of a biologically active agent directly administered to the site of disease. These can provide an effective, well-tolerated and convenient option for the serial treatment of metastases to achieve a sustained reduction in disease burden. 12 PV-10 is a sterile, non-pyrogenic 10% solution of
Rose Bengal (RB, 4,5,6,7-tetrachloro-2,4,5,7-tetraiodofluorescein disodium) that has been evaluated in both the in vitro and in vivo settings for the treatment of melanoma. 13, 14 PV-10 causes direct tumor lysis, promotes selective lymphocyte-mediated tumor destruction and is associated with a quantifiable local and systemic anti-tumor response, including a T-cell regulated abscopal effect in untreated lesions. [15] [16] [17] [18] PV-10 has been investigated both as a single agent and in combination therapy with radiotherapy. 14, 19 In a multi-center Phase II trial of 80 patients with Stage III-IV melanoma, PV-10 treatment produced a 51% overall response rate (ORR) and complete response (CR) in 50% when all disease was injected. 20 In another case series, IL PV-10 yielded an ORR of 52%, a complete response rate of 26% and bystander response in 50% of patients with non-target lesions. 21 Based on this clinical evidence, PV-10 treatment was continued at our institution after the completion of the Phase II trial, using the existing trial protocol in a selected cohort of patients.
It was hypothesized that IL PV-10 would provide disease-specific ablation of melanoma metastases without significantly compromising the treatment site and with limited systemic adverse effects. The purpose of this study was to further assess the clinical efficacy, safety profile and treatment outcomes of patients receiving IL PV-10 chemoablation therapy for the treatment of in-transit melanoma metastases. The aim was to identify predictors of treatment response and investigate the association with disease phenotype so that patients could be more suitably selected for PV-10 treatment.
2 | METHODOLOGY
| Study design
An open-label, non-comparative, non-randomized, prospective study was conducted using IL PV-10 for patients with accessible dermal and subcutaneous in-transit melanoma metastases. Patients were considered for treatment if they were over the age of 18 years, had histopathologically or cytologically confirmed metastases and measurable lesions >2 mm in diameter. Patients with both (AJCC 7th Ed.)
Stage III and IV disease were eligible for treatment provided they had failed or were not suitable for other locoregional therapies and were not better suited to systemic treatments as determined through discussion at a multidisciplinary meeting.
| Treatment protocol
Treatment under the Medicare Special Access Scheme (SAS) was approved by the appropriate human research ethics committee and hospital executive and all patients provided informed, written consent.
All clinically identified in-transit melanoma metastases were designated as "target lesions" then treated using PV-10. There were no "by-stander" or "non-target lesions" in this study. PV-10 was dispensed as a sterile, non-pyrogenic solution of 10% concentration Rose Bengal.
Following local anaesthetic infiltration, PV-10 was administered by intralesional injection. A fanning technique was used with a fine gauge needle to uniformly infiltrate target lesions and optimise the intratumoral distribution. The total dosage of PV-10 was limited to 1500 mg (ie, 15 mL of PV-10 solution) and was calculated using a standardized volumetric algorithm developed by Provectus Biopharmaceuticals and previously employed during the Phase II study.
Patients were monitored for immediate post-treatment adverse events (AEs) with additional short-term follow-up on days 1 and 7.
Patients were reviewed regularly with clinical visits during weeks 4, 8, and 12 following each PV-10 treatment. These visits included photodocumentation of study lesions, assessment of adverse events, and changes to concurrent medications and other medical conditions.
Other clinical evaluation included a physical examination, laboratory tests, evaluation of study lesions by a senior clinician with assessment of the best overall response and radiological surveillance of nonobservable regional and visceral lesions in accordance with the treatment protocol. If a complete response was not achieved and patients did not develop progressive disease, further PV-10 therapy was considered 4 weeks after treatment and this therapeutic approach was continued to facilitate multiple, consecutive PV-10 treatments.
Following the final PV-10 treatment, patients were assessed regularly at 3 monthly intervals within the outpatient setting until the the time of progressive disease or death. (PD). All lesions specified at baseline were followed over the course of the study. Adverse events (AEs) were assessed using the Common Terminology for Adverse Events (CTCAE) V3.0.
| Outcomes
The 
| Melanoma and in-transit characteristics
The characteristics of patients' primary melanoma are presented in Table 2 . The median time from primary melanoma diagnosis to develop (CR + PR + SD). The best overall response per treatment episode is presented in Table 3 During the study, the mortality rate was 48.9% and the median overall survival was 25.1 months from the first PV-10 treatment. The median OS was 66.2 months from the date of the primary melanoma diagnosis.
From the time of PV-10 treatment the 12-, 24-, 36-, and 48-month OS rates were 90.4%, 84.8%, 68.1%, and 64.5%, respectively (Kaplan-Meier survival estimate).
| Exploratory analysis
An exploratory analysis of variables predictive of complete response was performed (Table 4) . On univariate and multivariate analysis there 
| Toxicity
Every patient experienced at least one AE during the study (CTCAE grade 1 or 2). There were three treatment-associated grade 3 eventstreatment site ulceration, cellulitis, and photosensitivity reaction. There were no grade 4 or 5 AEs and no patient withdrew due to an AE ( Table 5 ).
The most common complaint was injection site oedema (62.2%), Table S1 ). 14, 20, 21 This prompted further investigation into predictors of treatment response in order to improve patient selection. The current study was conducted to further evaluate the efficacy and safety profile of PV-10 and assess important patient and disease factors correlating with complete response.
In this study, the per treatment episode ORR was 78.1% (where CR 30.5%, PR 47.6%), and the clinical benefit was 87.9%. Thompson et al reported on the outcomes of patients treated using PV-10 with complete and partial response rates of 26% and 25%, respectively on an ITT per lesion analysis. Given a substantial increase in CR to 50% and mean progression-free survival of 9.8 months observed when all disease was injected, it was suggested that treatment response was co-dependent on the untreated disease burden.
Consequently, in this study all clinically apparent disease was treated using PV-10 therapy. With multiple, consecutive interventions, the ORR increased to 86.6% (CR 42.2%, PR 44.4%) and the mean PFS duration was 5.0 months. These results complement both the Phase II results (ORR 71% with all treated lesions) and a parallel study where the ORR was 52%. 20, 21 The findings also corroborate the Phase I study results where the complete response rate was 27% and ORR was 55%, with a median follow-up duration of 28 months. 14 We report a cohort of patients with similar demographics and disease characteristics to those previously described. There also appeared to be a disproportionate quantity of disease involving the lower limbs (84.6%) compared to the expected distributions. 23 Prior to the availability of IL PV-10 at our institution, such patients would have been considered for isolated limb infusion (ILI). 24 Throughout the study period there was a trend away from this modality and the proportional use of ILI versus PV-10 decreased from Calmette-Guerin (BCG) (45%), and interleukin-2 (82%), the short duration of effect necessitated multiple treatment episodes. [25] [26] [27] In this study the durable response rate was 21.6% and this is promising when benchmarked against the DRR of 16.1% reported using T-VEC therapy. 26 Here, the ORR obtained using sequential PV-10 treatments was similar to those reported for isolated limb infusion and hyperthermic isolated limb perfusion (75% and 90%, respectively), while recognizing that such therapies are frequently employed in the setting of more advanced disease burden. [28] [29] [30] Advantages of PV-10 therapy compared with other intralesional agents include the robust response rates, low side effect profile and reduced treatment frequency.
In keeping with the variable natural history of locoregionally recurrent disease, the overall mortality was 48.9% and there was a 75.6% rate of locoregional progression following each treatment episode. Despite a modest survival advantage reported for certain patient sub-groups, there is currently no substantial evidence that directed locoregional therapies extend melanoma-specific survival. 30, 31 This study further supports this observation with a median OS time of 25 months following the first PV-10 treatment. The relative survival lengths of patients in this study, despite high locoregional recurrence rates and short PFS intervals underscore the need for further in vivo investigation of the "functional immune response" described with PV-10 treatment.
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On bivariate analysis, fewer than 15 lesions at the time of treatment was a predictor of a complete response (P = 0.03, Table S1 ). 14, [19] [20] [21] Outcomes stratified by lesion morphology and maximum size were not significant in this study, although other data suggest that low volume metastases, particularly individual lesion diameters <10 mm are significantly associated with complete response. 19, 20 Here, lesion morphology as a covariate may have been confounded by recruitment given that most patients selected for treatment had nodular lesions.
Overall, PV-10 treatment was well tolerated with a predominately locally limited side-effect profile consistent with the reported literature. [19] [20] [21] Despite multiple retreatment episodes there was a low rate (4.9%) of grade III/IV toxicity. While most patients developed swelling and transient pain at the injection site (CTCAE grades 1 or 2), in contrast to previous data, there was no correlation between blistering, ulceration or treatment severity and complete response. 19 The toxicity profile of PV-10 treatment is low compared with more invasive and potentially toxic therapies such as ILI or ipilimumab. 7, 28 The PV-10 treatment regimen also involved fewer treatment episodes and there is a significant reduction in treatmentrelated costs compared with systemic agents used for advanced disease.
Recent studies have focused on describing the functional immune response associated with PV-10 related tumor destruction. [15] [16] [17] [18] In vivo evidence demonstrates CD8+ T lymphocyte 
CONFLICTS OF INTEREST
The investigational agent PV-10 was provided free of commercial charge by Provectus Biopharmaceuticals. Dr Tavis 
